1.220USD+0.83%Mkt Cap: 77.09M USDP/E: —Last update: 2026-05-26
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap77.09M USD
Enterprise Value-65.95M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-149.34M USD
Revenue/Share—
Last Price1.220 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees49
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.20
PEG—
EV/EBITDA0.59
EV/Revenue—
P/S—
P/B0.42
EPS (TTM)-1.83
EPS (Forward)-1.03
52W Range
1.09015% of range1.950
52W High1.950 USD
52W Low1.090 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-82.42%
ROA-66.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-128.34M USD
CapEx (TTM)374.00K USD
FCF Margin—
FCF Yield-80.18%
Net Debt-142.11M USD
Net Debt/EBITDA1.28
Balance Sheet
Debt/Equity0.16
Current Ratio16.89
Quick Ratio16.50
Book Value/Sh2.949 USD
Cash/Share2.760 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.0 (Hold)
Target (Mean)2.667 USD
Target Range2.000 USD – 3.000 USD
# Analysts3
Ownership
Shares Out.61.92M
Float60.23M
Insiders2.35%
Institutions81.95%
Short Interest
Short Ratio6.5d
Short % Float5.67%
Short % Out.5.54%
Shares Short3.43M
Short (prev mo.)4.03M
Technical
SMA 501.259 (-3.1%)
SMA 2001.399 (-12.8%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)515.16K
Avg Vol (10d)495.35K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—